Discovery Labs names new CEO

Discovery Laboratories has chosen W. Thomas Amick as its next CEO. Amick has been interim CEO since August 2009. Last year, the FDA rejected Discovery's application for Surfaxin as a treatment for an infant respiratory ailment, questioning the test's ability to check on the quality changes that could occur over the course of the drug's shelf life. The developer hopes to file a complete response letter in early 2011. Discovery Labs release

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.